

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Protocol for an implementation study of an evidence-based home cardiac rehabilitation programme for people with heart failure and their caregivers in Scotland (SCOT:REACH-HF)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-040771
Article Type:	Protocol
Date Submitted by the Author:	24-May-2020
Complete List of Authors:	Purcell, Carrie; University of Glasgow, MRC/CSO SPHSU Daw, Paulina; University of Birmingham, School of Sport, Exercise & Rehabilitation Sciences Kerr, Claire ; University of Glasgow, Robertson Centre for Biostatistics Cleland , J; University of Glasgow, Robertson Center for Biostatistics Cowie, Aynsley ; University Hospital Crosshouse, Cardiac Rehabilitation Dalal, Hasnain; Royal Cornwall Hospitals NHS Trust, Research, Development and Innovation; University of Exeter Medical School, Primary Care Ibbotson, Tracy; University of Glasgow, Institute of Health and Wellbeing Murphy, Clare; NHS Greater Glasgow and Clyde, Royal Alexandra Hospital Taylor, Rod; University of Glasgow,
Keywords:	CARDIOLOGY, REHABILITATION MEDICINE, Heart failure < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

SCOT:REACH-HF Protocol paper v.3.0 200520 – from Protocol v1.1

1
2
3 **Title: Protocol for an implementation study of an evidence-based home**
4 **cardiac rehabilitation programme for people with heart failure and their**
5 **caregivers in Scotland (SCOT:REACH-HF)**
6
7
8
9

10
11
12
13 Authors:

14
15 Purcell, C., MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, 200
16 Renfield Street, Glasgow G2 3AX, carrie.purcell@glasgow.ac.uk (corresponding author)

17
18
19 Daw, P., School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham

20
21
22 Kerr, C., Robertson Centre for Biostatistics, University of Glasgow

23
24 Cleland, J.G., Robertson Centre for Biostatistics, University of Glasgow

25
26
27 Cowie, A., NHS Ayrshire and Arran, University Hospital Crosshouse

28
29
30 Dalal, H., Royal Cornwall Hospitals NHS Trust, University of Exeter

31
32 Ibbotson, T., Institute for Health and Wellbeing, University of Glasgow

33
34
35 Murphy, C., NHS Greater Glasgow and Clyde, Royal Alexandra Hospital

36
37
38 Taylor, R.S., MRC/CSO Social and Public Health Sciences Unit, University of Glasgow

39
40
41
42 And on behalf of the REACH-HF collaboration.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SCOT:REACH-HF Protocol paper v.3.0 200520 – from Protocol v1.1

ABSTRACT

Introduction: Despite evidence that cardiac rehabilitation (CR) is an essential component of care for people with heart failure, uptake is low. A centre-based format is a known barrier, suggesting that home-based programmes might improve accessibility. The aim of SCOT:REACH-HF is to assess the implementation of the REACH-HF home-based CR intervention in the context of the National Health Service (NHS) in Scotland.

This paper presents the design and protocol for this observational implementation study. Specific objectives of SCOT:REACH-HF are to: (i) assess service-level facilitators and barriers to the implementation of REACH-HF; (ii) compare real-world patient and caregiver outcomes to those seen in a prior clinical trial; and (iii) estimate the economic (health and social) impact of implementing REACH-HF in Scotland.

Methods and analysis: The REACH-HF intervention will be delivered in partnership with four 'Beacon sites' across six NHS Scotland Health Boards, covering rural and urban areas. Health professionals from each site will be trained to facilitate delivery of the 12-week programme to 140 people with heart failure and their caregivers. Patient and caregiver outcomes will be assessed at baseline and four-month follow-up. Assessments include the Minnesota Living with Heart Failure Questionnaire, EQ-5D-5L, Hospital Anxiety and Depression Scale, and the Caregiver Burden Questionnaire. Qualitative interviews will be conducted with up to 20 health professionals involved in programme delivery (e.g. cardiac nurses, physiotherapists). 65 facilitator-patient consultations will be audio-recorded and assessed for fidelity. Integrative analysis will address key research questions on fidelity, context and CR participant-related outcomes. The SCOT:REACH-HF findings will inform the future potential roll-out of REACH-HF in Scotland.

Ethics and dissemination: The study has been given ethical approval by the West of Scotland Research Ethics Service (reference 20/WS/0038, approved 25/03/2020). Written informed consent will be obtained from all participants. The research team will ensure that the study is conducted in accordance with both General Data Protection Regulations and the University of Glasgow's Research Governance Framework. Findings will be reported to the funder and shared with Beacon Sites, to facilitate service evaluation, planning and good practice. To broaden interest in, and understanding of REACH-HF, we will seek to publish in peer-reviewed scientific journals and present at stakeholder events, national and international conferences.

SCOT:REACH-HF Protocol paper v.3.0 200520 – from Protocol v1.1

ARTICLE SUMMARY

Strengths and limitations

- A formal study of the implementation of a novel home-based cardiac rehabilitation programme for heart failure in the context of NHS Scotland.
- Study employs mixed methods which integrate quantitative and qualitative approaches to understand the implementation process.
- Addresses home-based cardiac rehabilitation at a time of increased interest in, and need for, remote facilitation of care due to the COVID-19 pandemic.
- Although limited to four sites geographical sites, these sites incorporate a wide range of settings including urban and rural populations

KEYWORDS: cardiac rehabilitation, heart failure, implementation science, process evaluation, mixed methods

WORD COUNT [3969/4000]

SCOT:REACH-HF Protocol paper v.3.0 200520 – from Protocol v1.1

INTRODUCTION

Heart failure (HF) is both serious and common, and its prevalence is increasing[1,2]. Despite advances in care, people in Scotland with HF continue to have worse survival rates than those of some common cancers[3]. HF often has a negative effect on health-related quality of life (HRQoL) for those living with it[1,4], and carries a high risk of hospitalisation, a major driver of the economic burden[1,5].

Cardiac rehabilitation (CR) is highly effective, cost-effective and integral to comprehensive care of people with HF[6-8]. Self-care in HF is also widely acknowledged as important, and should also involve family members/caregivers, and promote self-efficacy[9]. A recent individual-participant data meta-analysis [7], and updated Cochrane review, show that, compared to no rehabilitation, CR participation reduces the risk of all-cause hospitalisation and improves HRQoL (assessed using the Minnesota Living with Heart Failure Questionnaire (MLHFQ))[8]. The 2019 National Heart Failure Audit reported that referral for CR was associated with a 12% reduction in mortality[10].

Despite this strong evidence, and national and international clinical guidelines recommending that anyone living with HF should receive CR, referral for and participation in CR remains low[8]. The National Audit of Cardiac Rehabilitation (NACR) found that only 57% of people with HF in England, Wales and Northern Ireland (Scottish data are not currently included in this audit) who were offered CR in 2018-19 attended one or more sessions [email communication from NACR]. Currently, most cardiac patients (77%) receive centre (hospital)-based, group CR[8]. Travelling to centres and dislike of group exercise are key barriers to participation in centre-based programmes[6,10,11]. That women, people from black and minority ethnic groups, and those living in high deprivation are less likely to attend centre-based CR[8], indicates that centre-based approaches are exclusionary. Home-based CR thus offers a cost-effective approach to improving CR uptake by people with HF, resulting in better health and wellbeing outcomes. The 2020 COVID-19 pandemic, and the policy by many countries of home lockdown to maintain social distancing, has dramatically underlined the urgent need for alternatives to centre-based models of healthcare provision.

We co-developed (with clinicians/practitioners, people with health failure, their caregivers and service commissioners) – an evidence- and theory-based, novel home-based CR intervention for people with HF: Rehabilitation EnAblement in CHronic Heart Failure (REACH-HF)[12]. A multi-centre randomised trial demonstrated that the addition of REACH-HF to usual medical care resulted in a clinically important improvement in HRQoL of people with HF, when compared to usual care alone[13]. Economic modelling showed that the REACH-HF intervention to be both low-cost (at £417/patient) and low-cost[14]. However, there remains a paucity of data regarding the extent to

SCOT:REACH-HF Protocol paper v.3.0 200520 – from Protocol v1.1

1
2
3 which introducing home-based CR for HF increases CR uptake[6,15]. Moreover, it is uncertain that
4 the positive outcomes identified in the REACH-HF RCT can be replicated in a ‘real world’ setting, and
5 what the key considerations might be with regards to embedding such an intervention in everyday
6 practice.
7
8
9

10 At present, relatively few evidence-based healthcare interventions become embedded in routine
11 clinical practice[16]. Factors contributing to this include: weak external validity of efficacy trials;
12 intervention developers’ lack of consideration for scale-up; trial design issues; and development of
13 interventions that are overly-theoretical[17-19]. Where implemented, evaluations often consider
14 individual-level health professional performance, targeting knowledge, routines and
15 attitudes[20,21]. Individuals play a significant role in implementation, in that they dynamically
16 engage with interventions while, to varying degrees, embodying their own interests and motivations
17 and those of their profession, organisation and culture[22,23]. It is crucial also to understand
18 community, organisational, system and policy-level influences on the embedding of innovative
19 practice[22].
20
21
22
23
24
25
26

27 Running parallel to a similar implementation study already underway in England and Northern
28 Ireland[24], our study seeks to understand the organisational and other wide-ranging influences
29 affecting the implementation of REACH-HF in Scotland, in order to inform potential future large-
30 scale roll-out of the intervention. A key factor shaping implementation is that a given intervention
31 may not produce the same effects when transferred from one context to another and, crucially,
32 from a randomised trial to the ‘real world’. Target population characteristics may differ in key ways,
33 such as geographical location (urban/rural) or relative deprivation. Moreover, there may be
34 significant contextual differences between sites and teams delivering a healthcare intervention, such
35 as the size of the team or familiarity with a given approach. Such contextual differences may
36 produce adaptations in what is delivered and how (i.e. impacting fidelity to the intervention design).
37 This may in turn shape intervention results – including any proven benefit – when compared with an
38 RCT[25]. Adaptability to context may also impact the sustainability of an intervention, that is, the
39 extent to which it is embedded in everyday practice[22].
40
41
42
43
44
45
46
47
48
49

50 We draw specifically from UK Medical Research Council (MRC) guidance on evaluation of complex
51 interventions, particularly using process evaluation methodology[26]. Process evaluation is an
52 established means by which to understand implementation by assessing: fidelity (the degree to
53 which the intervention was delivered as intended); context (barriers to and facilitators of
54 implementation, including those that might explain variation in outcomes), and mechanisms of
55 impact[23]. As the mechanisms by which the REACH-HF intervention changes behaviour have been
56 described and explored elsewhere[12,13], we focus here on fidelity and context in the new delivery
57
58
59
60

SCOT:REACH-HF Protocol paper v.3.0 200520 – from Protocol v1.1

setting. Integration of process and outcome data can generate better understanding of, for example, whether and how adaptations to implementation, or differences amongst sites, explains any observed variation in outcomes, as well as informing improvements for future roll-out.

METHODS AND ANALYSIS

Study design

A mixed-method implementation study comprising a multi-centre prospective cohort study and nested process and economic evaluations.

The overarching aim of this study is to assess the real-world implementation REACH-HF for people living with heart failure and their caregivers in Scotland. Our research questions are:

1. what are the service level facilitators and barriers to the implementation of REACH-HF?
2. how do 'real-world' patient and caregiver outcomes compare with those seen in a prior clinical trial?
3. what is the estimated economic (health and social) impact of implementing REACH-HF in Scotland?

Informed by process evaluation methodology, the study protocol detailed below is thus organised around four key components, which contribute to answering these questions:

- **fidelity** of implementation: what was implemented and how closely this reflected what was intended (i.e. the original REACH-HF intervention) [RQ1&2];
- **contextual factors**: barriers to, and facilitators of, implementation, as perceived by the health professionals and service organisers involved; 'background noise' to implementation [RQ1];
- **CR participant-related outcomes**: whether, and to what extent, improvements in patient outcomes seen in the REACH-HF RCT are replicated [RQ2];
- **economic impact**: health and social implementation costs [RQ3].

The study will be conducted across Scottish NHS Health Board CR services which, as early adopters of REACH-HF, will be designated as 'Beacon Sites'. (The use of early adopters to model intervention implementation is itself one means of contributing to routinisation/embedding of innovative practice[22].) A national application process followed promotion at national conferences, and contact letters to HF specialist nurses and cardiac rehabilitation leads. This resulted in recruitment of four sites across six NHS Health Boards to act as Beacon Sites: NHS Ayrshire and Arran; NHS

SCOT:REACH-HF Protocol paper v.3.0 200520 – from Protocol v1.1

Lanarkshire; NHS Forth Valley; and NHS Highland, Orkney, and Shetland (combined to act as one site due to small patient numbers). Sites were selected for their ability to commit to delivery of REACH-HF, and for geographic spread.

Sites will assess patient outcomes before and after administering the 12-week intervention/programme with 35 people with heart failure (140 total). Members of the HF team at each site will be interviewed. Detailed information of the costs and utilisation of the provision of the REACH-HF programme will be collected. Given the ongoing COVID-19 crisis, the start of data collection for the study has been delayed, but is provisionally planned to begin in September/October 2020. NHS Greater Glasgow and Clyde will act as study sponsor.

Sample and recruitment

The study will be conducted across Scottish NHS 'Beacon Sites'. People with heart failure (HF) are eligible if they: are aged 18 years or over; have a confirmed diagnosis of systolic (reduced ejection fraction) heart failure within the past five years; have experienced no deterioration of HF symptoms in the preceding two weeks resulting in hospitalisation or alteration of HF medication; and are deemed suitable for CR by their local clinical team. We will exclude anyone who: has undertaken CR in the preceding 12 months; has medical contraindications to exercise testing or training; is in a long-term care establishment, or unwilling/unable to travel to research assessments or accommodate home visits; is unable to understand the study information or unable to complete the outcome questionnaires. Patients with a caregiver will also be invited to participate. Patients with no caregiver, or whose caregivers do not wish to participate, are still eligible take part in the study.

Sites will recruit people with HF, using their usual means of CR referral to introduce the study. This is likely to include a variety of pathways such as: people with HF referred for CR from acute or primary care; review of patients held on site HF databases; and approaching people with HF at outpatient appointments/home-visits. Potential participants will be provided with invitation letters, information sheets, and reply slips for both them and their caregiver (if applicable), and those interested in participation will be asked to instigate contact with the research team by returning the reply slips.

Fig 1 outlines the participation pathway for people with HF.

[FIGURE 1 HERE]

A maximum of 20 individual interviews will be conducted with health professionals involved in the delivery of SCOT:REACH-HF, near the end of the intervention period. These will include the trained facilitators (typically HF and CR nurses or physiotherapists), as well as other key individuals involved

SCOT:REACH-HF Protocol paper v.3.0 200520 – from Protocol v1.1

1
2
3 in co-ordinating and commissioning CR (such as senior clinicians and service management). There
4 may be some variation in participant roles due to the differing structures of local HF teams. We will
5 use a combination of convenience and purposive sampling, offering the opportunity to participate to
6 all those delivering REACH-HF, and those identified as having a key role in service planning, to ensure
7 capture of diverse perspectives. A participant information sheet will be provided to all potential
8 interviewees, and they will have adequate time to consider participation and ask questions about
9 the interview process. Written consent will be obtained prior to face-to-face interviews. Where
10 interviews are to be conducted by telephone, consent forms will be completed digitally and returned
11 by email, and verbal consent recorded digitally.

21 **The intervention**

22
23 REACH-HF is a home-based, health professional-facilitated, 12-week CR programme supporting self-
24 care in patients with HF. Three health professionals with CR and/or HF experience from each Beacon
25 Sites will attend a two to three day REACH-HF training course delivered by the Heart Manual
26 Department. Training focuses on the seven steps of successful facilitation of REACH-HF (in turn
27 based on a person-centred care approach): 1) Build rapport; 2) Assess needs and build
28 understanding of HF; 3) Support self-management and progress monitoring; 4) Discuss exercise and
29 wellbeing; 5) Summarise and plan next steps; 6) Review progress; 7) Support long-term
30 maintenance. As such, training includes sessions on psychology, behaviour change, physical activity,
31 engaging caregivers, and additional components which were designed to give overall coherence to
32 the training. Following training, facilitators are then asked to implement REACH-HF. The programme
33 – described in detail elsewhere[11,12] – is outlined in BOX A.

34
35
36
37
38
39
40
41
42
43 **[BOX A HERE]**

44 **Measures / data collection**

45
46
47 Patient and caregiver outcome data will be collected during an assessment clinic visit by a
48 designated member of the Beacon Site team trained in data collection by the research/REACH-HF
49 team. Data will be collected at baseline - before commencing with the REACH-HF programme - and
50 four months following baseline, which coincides with the end of intervention delivery period (see
51 Figure 1).

SCOT:REACH-HF Protocol paper v.3.0 200520 – from Protocol v1.1

1
2
3 Fidelity assessment: Facilitator-patient interactions (face-to-face and/or phone) for 65 participants
4 will be audio-recorded. Recordings will be assessed using our established fidelity assessment
5 checklist (described in detail elsewhere [12]). This 12-item checklist focuses on assessing inclusion by
6 facilitators of key processes such as patient-centred communication, making a plan of action, and
7 encouraging self-monitoring of progress.
8
9

10
11 Additionally, facilitators will be asked to complete a brief self-rated fidelity checklist after every
12 session. This comprises questions on the same 12 programme components and asks facilitators to
13 rate occurrences of each feature (absent, minimal, some, sufficient, good, very good, excellent). An
14 independent observer-rating is resource-intensive, while self-rated assessment may provide a
15 pragmatic, real-world alternative to monitor delivery quality. We will also explore (in the interviews
16 below) whether use of the checklist facilitates/encourages reflexive practice and, in doing so, quality
17 of implementation.
18
19
20
21
22
23

24
25
26 Context: We seek to capture data on barriers to and facilitators of implementation REACH-HF by
27 interviewing health professionals at each Beacon Site. We anticipate conducting up to 20 individual
28 interviews, which will be audio-recorded and transcribed verbatim for analysis. Interviews will be
29 conducted by CP face-to-face or by phone, as per the participant's preference. Normalisation
30 Process Theory [26] will be used as a theoretical framework to guide data collection, analysis and
31 interpretation. A topic guide will be developed based on the four constituent constructs of NPT
32 (coherence, cognitive participation, collective action, reflexive monitoring), the existing literature on
33 home/cardiac rehabilitation, and the key aims of the implementation study, while also allowing for
34 the capture of factors unanticipated by the research team.
35
36
37
38
39
40

41
42 Contextual data from each site will be recorded via an implementation log (Excel file) which will also
43 capture overall 'background noise' to implementation (such as the impact of the COVID-19
44 pandemic) which will contribute to the contextual analysis.
45
46
47
48
49

50 CR participant-related outcomes: Data will be recorded in a Case Report Form (CRF). At the baseline
51 clinic visit, after obtaining written consent, Beacon Site teams will collect detailed sociodemographic
52 data (age, gender, ethnicity, weight, employment status, education level, smoking status) and
53 medical history from the participants' hospital and primary care records, including: comorbidities
54 (number and severity scored with Charlson co-morbidity index); New York Heart Association (NYHA)
55 class; heart failure aetiology; concomitant heart failure medication and presence of implantable
56 heart failure devices.
57
58
59
60

SCOT:REACH-HF Protocol paper v.3.0 200520 – from Protocol v1.1

The following patient outcomes will be assessed: disease-specific health-related quality of life (HRQoL) measured using the Minnesota Living with Heart Failure Questionnaire; generic quality of life (five-dimension EuroQol (EQ-5D-5L) scale); psychological wellbeing (Hospital Anxiety and Depression Scale (HADS)); patient-reported outcome measure for cardiac rehab (PROM-CR); exercise capacity (incremental shuttle walk test); hospitalisations and primary care contacts (number, reason, duration); adverse events (e.g. skeletomuscular injury); health literacy (Health Literacy Questionnaire (HLQ)). Caregiver outcomes are: generic quality of life (EQ-5D-5L); psychological wellbeing (HADS); Family Caregiver Quality of Life Scale questionnaire (FamQol); Caregiver Burden Questionnaire HF (CBQ-HF); Caregiver Contribution to Self-care of HF Index questionnaire (CC-SCHF). The same outcomes will be collected at the four-month follow up.

Economic impact: Data will be collected to allow the costing of the REACH-HF intervention delivery. These will include time input from REACH-HF facilitators, supervision for facilitators, training costs for facilitators and consumables. This will be captured via facilitator self-report in the course of the intervention (part of the implementation log). Unit costs for resource use will be sought from national published or NHS sources. Data from each site will be recorded in the implementation log (excel file, as above).

Data management

Data management will follow the principles of Good Clinical Practice and supported by the University of Glasgow Clinical Trials Unit (UoG CTU). An electronic CRF (eCRF) developed by the CTU will capture all data noted above. Access to the eCRF will be restricted, via a study-specific web portal, with only authorised personnel able to make entries. RST or their designee will be responsible for all eCRF entries, and will confirm that data are accurate, complete and verifiable. Entries will be made locally by Beacon Site staff trained by the research team, or at UoG where local capacity does not permit this. In this instance, hard copy CRFs will be securely couriered to UoG for data entry. Where practical, data will be validated at the point of entry into the eCRF. Any additional data discrepancies will be flagged to RST and any changes recorded to maintain a complete audit trail (reason, date and who made the change). Data will be stored in a MS SQL Server database. Direct access to the study web portal will be granted, on request, to authorised representatives of the Sponsor, host institution and regulatory authorities to permit trial-related monitoring, audits and inspections.

SCOT:REACH-HF Protocol paper v.3.0 200520 – from Protocol v1.1

The qualitative, fidelity and economic impact components of the study will be conducted by UoG under the direction of RST. Transcription will be undertaken by a specialist service with whom UoG has an ongoing contractual arrangement and confidentiality agreement. All data (Excel files, audio recordings and anonymised transcripts, stored separately) will be kept for at least ten years in line with UoG Research Governance Framework Regulations for clinical research. Data will be stored confidentially on password-protected servers maintained on the UoG network. Anonymised data will be made available to other legitimate researchers on request, as per study consents.

The study will be overseen by the Project Management Group (co-applicants) and Project Advisory Group (national CR experts) – see Appendix 1 for membership.

Data Analysis

We require 130 participants to detect pre-post intervention change in the Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores to achieve the minimal important difference [13] ≥ 5 points. This calculation is based on a MLHFQ standard deviation of 24 points, within patient pre-post correlation ($r=0.72$) and attrition rate of $\leq 10\%$ as seen in our multi-centre RCTs refs). There is no formal sample size calculation for the number of caregivers participating in this study.

Fidelity: Fidelity data will be analysed by CP. Fidelity checklist scores will be collated at facilitator, site, and total sample levels. We will present descriptive statistics (means, ranges), using the same analytic approach as the original REACH-HF trial [13]. In brief, the fidelity checklist uses an established 0-6 scale (Dreyfus scale of clinical skills acquisition[28]) to rate clinical skills, and is anchored such that a score of three or more represents adequate delivery quality for each item. Fidelity outcomes will be compared with the REACH-HF RCT [13], and analysed alongside self-rated fidelity scores. Overall findings will be integrated with the context and CR participant-related outcome data findings.

CR participant-related outcomes: The primary analyses for primary and secondary quantitative outcomes will be based on a within-patient comparison in participants with complete outcome data at four months. We will examine the characteristics of any patients who withdraw, and conduct secondary analysis based on imputation of their missing outcome data. All within-patient outcome comparisons will be presented as mean difference with 95% CI. Statistical analysis will be conducted by RST using STATA v.15. Descriptive statistics will be presented in order to describe study population characteristics.

SCOT:REACH-HF Protocol paper v.3.0 200520 – from Protocol v1.1

1
2
3 Context: Verbatim transcripts (Word documents) will be pseudonymised (removing any potential
4 indicators of personal identity or site) and uploaded into NVivo 12 qualitative software to facilitate
5 data management. A coding framework will be developed, informed by the constructs of NPT noted
6 above, and taking an approach informed by the Framework method[29]. This approach will also for
7 consideration of unanticipated issues.
8
9

10
11
12 Following this categorising stage, a further interpretive stage will see data examined across sources
13 (professional role) and cases (sites). This will facilitate understanding of contextual factors shaping
14 implementation of REACH-HF in context, and development of potential explanations for
15 commonalities and differences between our findings and the previous RCT.
16
17

18
19 A subsequent integrative analysis will be conducted to bring together each analytic component
20 (fidelity, context, CR participant-related outcomes). Integrative analysis will involve placing all
21 relevant data in one integrative matrix and assessing for synergies which indicate out key findings.
22
23 First stage coding, interpretation will be conducted by CP in consultation with RST. Subsequent
24 integrative analysis will be conducted by CP and RST with input from the project management group.
25
26

27
28 Economic impact: Economic analysis will focus on assessing the cost of the delivery of REACH-HF in
29 the four Beacon Sites, that is, the additional (incremental) costs associated with delivery of the HF
30 Manual, when added to usual care. EA will be conducted by CP and RST alongside the main statistical
31 analysis.
32
33
34

35 36 37 38 **Patient Public Involvement (PPI)** 39

40
41 People with heart failure and their caregivers had an extensive input into the development of the
42 REACH-HF intervention [13,14]. We will establish a standing PPI group for SCOT:REACH-HF led by TI.
43 Four meetings of the PPI group will be convened during the study to review participant-facing
44 materials, advise on dissemination, and provide input on any participant related problems that may
45 arise, such as recruitment and retention.
46
47
48
49

50 51 52 **Discussion** 53

54
55 Approaches to implementation science are varied[23]. We draw on MRC guidance on the evaluation
56 of complex interventions which highlights that, while RCTs are viewed by many as the gold standard
57 for demonstrating efficacy, they do not tell policy makers or service commissioners whether an
58 intervention would produce the same outcomes in their context[26]. A process evaluation approach
59
60

SCOT:REACH-HF Protocol paper v.3.0 200520 – from Protocol v1.1

1
2
3 produces understanding of implementation by assessing fidelity, context, and mechanisms of
4 impact[25]. As the mechanisms of REACH-HF are explored elsewhere[12,13], this study focuses on
5 fidelity and context in the new delivery setting.
6
7

8
9 Most complex interventions would be expected to see some adaptation as they are transferred into
10 real world settings[23] (variable by how much contextual factors have been considered in the design
11 process). Indeed, some adaptability is in fact desirable in order to support effectiveness[30]. In order
12 to assess if and how any adaptations might have impacted the overall integrity of the intervention, it
13 is vital to a) have a clear picture ahead of implementation of what the active components of an
14 intervention are, and b) understand how closely delivery follows what is intended[30]. Hence, we
15 include above a description of the intervention's constituent parts, and include in the study design a
16 multi-pronged approach to assessing fidelity.
17
18
19
20
21

22
23 There are limitations on the degree to which novel interventions become embedded in routine
24 clinical practice. However, these limitations can be ameliorated by well-considered studies of
25 implementation. By operationalising a tailored process evaluation methodology, we aim to assess
26 such implementation, and the translation from RCT to 'real world', by paying particular attention to:
27 fidelity to the intended programme, contextual factors shaping delivery, and how these may explain
28 any differences measured in participant outcomes.
29
30
31
32

33
34 Our findings will inform potential larger-scale roll-out of REACH-HF, offer guidance to policy makers
35 and CR commissioners, inform contextual adaptations, and facilitate diffusion and embedding of
36 home-based CR for people with heart failure in the UK.
37
38
39
40

41 **Strengths and limitations**

42
43 This study will formally assess of the implementation of a novel home-based cardiac rehabilitation
44 programme for heart failure in the context of NHS Scotland. It employs mixed methods which
45 integrate quantitative and qualitative approaches to understanding the implementation process.
46
47 Moreover, our study will facilitate a communication channel between researchers and
48 implementers, in order to support high quality services for people with heart failure, and establish
49 four key Beacon Sites that have the potential to model intervention roll-out, should that be adopted
50 more widely. Although limited to four sites geographical sites, these sites incorporate a wide range
51 of settings including urban and rural populations.
52
53
54
55
56
57
58
59
60

SCOT:REACH-HF Protocol paper v.3.0 200520 – from Protocol v1.1

REFERENCES

1. National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management. *NICE Guideline NG106*. London: NICE; 2018.
2. Conrad N, Judge A, Tran J et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. *Lancet* 2018;391(10120):572-80.
3. Mamas MA, Sperrin M, Watson MC et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. *Eur J Heart Fail* 2017;19(9):1095-104.
4. Braunwald, E. The war against heart failure: The Lancet lecture. *Lancet* 2015;385(9970):812-24.
5. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. *Int J Cardiol* 2014;171(3):368-76.
6. Dalal HM, Doherty P, Taylor RS. Cardiac rehabilitation. *BMJ* 2015;351:h5000.
7. Long L, Mordi IR, Bridges C et al. Exercise-based cardiac rehabilitation for adults with heart failure. *Cochrane Database Syst Rev* 2019;1:Cd003331
8. Taylor RS, Walker S, Smart NA et al. Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure: individual participant meta-analysis. *J Am Coll Cardiol* 2019;73(12):1430-43.
9. Spaling MA, Currie K, Strachan PH, Harkness K, Clark AM. Improving support for heart failure patients: A systematic review to understand patients' perspectives on self-care. *J Adv Nurs* 2015;71(11):2478-89.
10. National Cardiac Audit Programme. National Heart Failure Audit: 2016/17 summary report. London: NICOR; 2017.
11. The National Audit of Cardiac Rehabilitation: annual statistical report 2018. London: British Heart Foundation;2018.
12. Greaves CJ, Wingham J, Deighan C et al. Optimising self-care support for people with heart failure and their caregivers: Development of the Rehabilitation Enablement in Chronic Heart Failure (REACH-HF) intervention using intervention mapping. *Pilot Feasibility Stud* 2016;2:37.

SCOT:REACH-HF Protocol paper v.3.0 200520 – from Protocol v1.1

13. Dalal HM, Taylor RS, Jolly K et al. The effects and costs of home-based rehabilitation for heart failure with reduced ejection fraction: The REACH-HF multicentre randomized controlled trial. *Eur J Prevent Cardiol* 2019;26(3):267-72.
14. Taylor RS, Sadler S, Dalal HM et al. The cost effectiveness of REACH-HF and home-based cardiac rehabilitation compared with the usual medical care for heart failure with reduced ejection fraction: a decision model-based analysis. *Eur J Prev Cardiol* 2019;26(12):1252-1261.
15. Santiago de Araujo Pio C, Chaves GS, Davies P, Taylor RS, Grace SL. Interventions to promote patient utilisation of cardiac rehabilitation. *Cochrane Database Syst Rev* 2019;2:Cd007131.
16. Balas EA, Boren SA Managing Clinical Knowledge for Health Care Improvement, in *Yearbook of Medical Informatics 2000: Patient-centered Systems*. 2000; Stuttgart: Schattauer: 67-70.
17. Schliep ME, Alonzo CN, Morris MA. Beyond RCTs: Innovations in research design and methods to advance implementation science. *Evid Based Commun Assess Interv* 2018;11(3-4):82-98.
18. Goldstein H, Olswang L Is there a science to facilitate implementation of evidence-based practices and programs? *Evid Based Commun Assess Interv* 2017;11(3-4):55-60.
19. Glanz K, Bishop DB. The role of behavioral science theory in development and implementation of public health interventions. *Annu Rev Public Health* 2010;31:399-418.
20. Grol RPTM, Bosch MC, Hulscher MEJL, Eccles MP, Wensing M. Planning and Studying Improvement in Patient Care: The Use of Theoretical Perspectives. *Milbank Q* 2007;85(1):93-138.
21. Grimshaw JM, Thomas RE, MacLennan G et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. *Health Technology Assessment*. 2004;8(6):1-72.
22. Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O. Diffusion of Innovations in Service Organizations: Systematic Review and Recommendations. *Milbank Q*. 2004;82(4):581-629.
23. Damschroder LJ, Aron DC, Keith RE et al. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. *Implementation Sci* 2009;4(50).
24. Daw P, van Beurden S, Greaves C et al. Getting evidence into clinical practice: Protocol for evaluation of the implementation of a home-based cardiac rehabilitation programme for patients with heart failure. *BMJ Open*. Accepted (May 2020).
25. Fixsen DL, Naoom SF, Blase KA, et al. *Implementation Research: A Synthesis of the Literature*. Tampa: University of South Florida; 2005.

SCOT:REACH-HF Protocol paper v.3.0 200520 – from Protocol v1.1

26. Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions: Medical Research Council guidance. *BMJ* 2015;350:1258.

27. May CR, Cummings A, Girling M et al. Using Normalization Process Theory in feasibility studies and process evaluations of complex healthcare interventions: a systematic review. *Implementation Sci* 2018;13(1):80.

28. Dreyfus HL. The Dreyfus model of skill acquisition. In J. Burke (ed.) *Competency based education and training*. 1989; London: Falmer Press.

29. Ritchie J, Spencer L. Qualitative data analysis for applied policy research, in Bryman A, Burgess RG (eds.) *Analysing qualitative data*. 1994; London: Routledge.

30. Hawe P, Shiell A, Riley T. Complex interventions: how “out of control” can a randomised controlled trial be?. *BMJ* 2004;328(7455):1561-3.

AUTHOR CONTRIBUTIONS

The study was conceived of and designed by RST, HD and the REACH-HF collaboration. CP and RST drafted the manuscript. RST and CP will lead recruitment and set-up of Beacon Sites, and CP will oversee day-to-day project management. RST, CK and CP secured all relevant ethical approvals for the project and prepared all study documentation. AC designed the PROM-CR measure. CP and RST will conduct study analysis and write-up. All other authors will provide project supervision and oversight, and all reviewed and approved the final version of this protocol for publication.

FUNDING STATEMENT

This work is supported by Heart Research UK (grant SC09/19) and conducted by the MRC/CSO Social and Public Health Sciences Unit, University of Glasgow (grants SPHSU14 and MC_UU_12017/14). RST is part-funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research scheme (project reference RP-PG-1210-12004).

COMPETING INTERESTS STATEMENT

None.


FIGURE LEGEND

BOX A - The REACH-HF Intervention

Figure 1 - SCOT:REACH-HF Participant Pathway

BOX A: The REACH-HF Intervention

- *The Heart Failure Manual*, which provides information about HF for the person with heart failure, to increase understanding of the condition and address common misconceptions.
- Information on and strategies for managing HF, and further relevant advice on, for example, managing lifestyle risk, managing depression and anxiety, and getting support from others.
- A choice of two exercise training programmes: a chair-based programme (via DVD and online) and a walking programme; with a recommendation that these should be engaged in three times weekly, alongside general physical activity.
- A stress-management programme, with relaxation techniques (provided in the manual and in audio format) to help cope with anxiety and depression.
- A progress tracker designed to facilitate an individual's learning from experience through self-monitoring of behaviour and symptoms. (This prompts help-seeking as appropriate).
- *A Family and Friends Resource* to increase caregiver understanding of HF, to enable them to support the person with HF's self-care and wellbeing.
- Face-to-face and telephone facilitation over 12 weeks by a health professional trained to deliver the REACH-HF programme.



1
2
3 **Appendix 1 – Project Management Group and Independent Advisory Group Membership**
4
5
6
7

8 **Project Management Group** *(To oversee the progress and delivery of the project)*
9

10 Prof Rod Taylor - Chief Investigator, University of Glasgow
11

12 Dr Carrie Purcell – Project Manager, University of Glasgow
13

14
15 Dr Hayes Dalal – REACH-HF co-Chief Investigator / Honorary Clinical Associate Professor, University
16 of Exeter / Senior Clinical Researcher, Royal Cornwall Hospitals NHS Trust
17

18
19 Dr Clare Murphy - Co-Applicant, NHS Greater Glasgow & Clyde / Scottish National Advisory
20 Committee for Heart Disease – Heart Failure Subgroup Chair and Clinical Lead
21

22
23 Dr Aynsley Cowie – Co-Applicant, Consultant Physiotherapist in Cardiology, NHS Ayrshire & Arran /
24 BACPR Council Member
25

26
27 Dr Tracy Ibbotson – Co-Applicant, Patient and Public Involvement and Engagement Lead, College of
28 Medical, Veterinary and Life Sciences, University of Glasgow
29

30 Mrs Claire Kerr – Project Manager, Robertson Centre for Biostatistics, University of Glasgow
31
32
33
34
35

36 **Project Advisory Group** *(To provide independent advice and direction to the project)*
37
38
39
40

41 Ms Frances Divers – Cardiac Rehabilitation Champion, NHS Scotland (chair)
42

43 Dr Edwin Jesudason – Cardiac Rehabilitation Clinical Lead, NHS Scotland
44

45 Mr Richard Forsyth – Health Services Engagement Lead, British Heart Foundation Scotland
46

47 Mr Nick Hartshorne-Evans – CEO, Pumping Marvellous (patient group)
48

49 Ms Louise Taylor – Head of Services, Heart Manual Department, NHS Lothian
50

51
52 Dr Hayes Dalal – REACH-HF co-Chief Investigator / Honorary Clinical Associate Professor, University
53 of Exeter / Senior Clinical Researcher, Royal Cornwall Hospitals NHS Trust
54

55
56 Ms Helen Wilson, Head of Research, Heart Research UK (observer)
57
58
59
60

BMJ Open

Protocol for an implementation study of an evidence-based home cardiac rehabilitation programme for people with heart failure and their caregivers in Scotland (SCOT:REACH-HF)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-040771.R1
Article Type:	Protocol
Date Submitted by the Author:	18-Aug-2020
Complete List of Authors:	Purcell, Carrie; University of Glasgow, MRC/CSO SPHSU Daw, Paulina; University of Birmingham, School of Sport, Exercise & Rehabilitation Sciences Kerr, Claire ; University of Glasgow, Robertson Centre for Biostatistics Cleland , J; University of Glasgow, Robertson Center for Biostatistics Cowie, Aynsley ; University Hospital Crosshouse, Cardiac Rehabilitation Dalal, Hasnain; Royal Cornwall Hospitals NHS Trust, Research, Development and Innovation; University of Exeter Medical School, Primary Care Ibbotson, Tracy; University of Glasgow, Institute of Health and Wellbeing Murphy, Clare; NHS Greater Glasgow and Clyde, Royal Alexandra Hospital Taylor, Rod; University of Glasgow,
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Rehabilitation medicine
Keywords:	CARDIOLOGY, REHABILITATION MEDICINE, Heart failure < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

SCOT:REACH-HF Protocol paper v.3.1 040820

1
2
3 **Title: Protocol for an implementation study of an evidence-based home**
4 **cardiac rehabilitation programme for people with heart failure and their**
5 **caregivers in Scotland (SCOT:REACH-HF)**
6
7
8
9

10
11
12
13 Authors:

14
15 Purcell, C., MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Berkeley
16 Square, 99 Berkeley Street, Glasgow G3 7HR, carrie.purcell@glasgow.ac.uk (corresponding
17 author)
18
19

20
21 Daw, P., School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham
22

23
24 Kerr, C., Robertson Centre for Biostatistics, University of Glasgow
25

26
27 Cleland, J., Robertson Centre for Biostatistics, University of Glasgow
28

29
30 Cowie, A., NHS Ayrshire and Arran, University Hospital Crosshouse
31

32
33 Dalal, H., Royal Cornwall Hospitals NHS Trust, University of Exeter
34

35
36 Ibbotson, T., Institute for Health and Wellbeing, University of Glasgow
37

38
39 Murphy, C., NHS Greater Glasgow and Clyde, Royal Alexandra Hospital
40

41
42 Taylor, R., MRC/CSO Social and Public Health Sciences Unit & Robertson Centre for
43
44 Biostatistics, University of Glasgow
45

46 And on behalf of the REACH-HF collaboration.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SCOT:REACH-HF Protocol paper v.3.1 040820

ABSTRACT

Introduction: Despite evidence that cardiac rehabilitation (CR) is an essential component of care for people with heart failure, uptake is low. A centre-based format is a known barrier, suggesting that home-based programmes might improve accessibility. The aim of SCOT:REACH-HF is to assess the implementation of the REACH-HF home-based CR intervention in the context of the National Health Service (NHS) in Scotland.

This paper presents the design and protocol for this observational implementation study. Specific objectives of SCOT:REACH-HF are to: (i) assess service-level facilitators and barriers to the implementation of REACH-HF; (ii) compare real-world patient and caregiver outcomes to those seen in a prior clinical trial; and (iii) estimate the economic (health and social) impact of implementing REACH-HF in Scotland.

Methods and analysis: The REACH-HF intervention will be delivered in partnership with four 'Beacon sites' across six NHS Scotland Health Boards, covering rural and urban areas. Health professionals from each site will be trained to facilitate delivery of the 12-week programme to 140 people with heart failure and their caregivers. Patient and caregiver outcomes will be assessed at baseline and four-month follow-up. Assessments include the Minnesota Living with Heart Failure Questionnaire, EQ-5D-5L, Hospital Anxiety and Depression Scale, and the Caregiver Burden Questionnaire. Qualitative interviews will be conducted with up to 20 health professionals involved in programme delivery (e.g. cardiac nurses, physiotherapists). 65 facilitator-patient consultations will be audio-recorded and assessed for fidelity. Integrative analysis will address key research questions on fidelity, context and CR participant-related outcomes. The SCOT:REACH-HF findings will inform the future potential roll-out of REACH-HF in Scotland.

Ethics and dissemination: The study has been given ethical approval by the West of Scotland Research Ethics Service (reference 20/WS/0038, approved 25/03/2020). Written informed consent will be obtained from all participants. The study is listed on the ISRCTN registry with study ID ISRCTN53784122. The research team will ensure that the study is conducted in accordance with both General Data Protection Regulations and the University of Glasgow's Research Governance Framework. Findings will be reported to the funder and shared with Beacon Sites, to facilitate service evaluation, planning and good practice. To broaden interest in, and understanding of REACH-HF, we will seek to publish in peer-reviewed scientific journals and present at stakeholder events, national and international conferences.

1 SCOT:REACH-HF Protocol paper v.3.1 040820

2
3 **ARTICLE SUMMARY**

4
5 **Strengths and limitations**

- 6
7
- 8 • A formal study of the implementation of a novel home-based cardiac rehabilitation
9 programme for heart failure in the context of NHS Scotland.
 - 10 • Study employs mixed methods which integrate quantitative and qualitative approaches to
11 understand the implementation process.
 - 12 • Addresses home-based cardiac rehabilitation at a time of increased interest in, and need for,
13 remote facilitation of care due to the COVID-19 pandemic.
 - 14 • Although limited to four sites geographical sites, these sites incorporate a wide range of
15 settings including urban and rural populations
- 16
17
18
19
20
21

22 **KEYWORDS:** cardiac rehabilitation, heart failure, implementation science, process evaluation, mixed
23 methods
24

25
26
27
28 **WORD COUNT [3969/4000]**
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SCOT:REACH-HF Protocol paper v.3.1 040820

INTRODUCTION

Heart failure (HF) is both serious and common, and its prevalence is increasing[1,2]. Despite advances in care, people in Scotland with HF continue to have worse survival rates than those of some common cancers[3]. HF often has a negative effect on health-related quality of life (HRQoL) for those living with it[1,4], and carries a high risk of hospitalisation, a major driver of the economic burden[1,5].

Cardiac rehabilitation (CR) is highly effective, cost-effective and integral to comprehensive care of people with HF[6-8]. Self-care in HF is also widely acknowledged as important, and should also involve family/friends, and promote self-efficacy[9]. A recent individual-participant data meta-analysis [7], and updated Cochrane review, show that, compared to no rehabilitation, CR participation reduces the risk of all-cause hospitalisation and improves HRQoL (assessed using the Minnesota Living with Heart Failure Questionnaire (MLHFQ))[8]. The 2019 National Heart Failure Audit reported that referral for CR was associated with a 12% reduction in mortality[10].

Despite this strong evidence, and national and international clinical guidelines recommending that anyone living with HF should receive CR, referral for and participation in CR remains low[8]. The National Audit of Cardiac Rehabilitation (NACR) found that only 57% of people with HF in England, Wales and Northern Ireland (Scottish data are not currently included in this audit) who were offered CR in 2018-19 attended one or more sessions [email communication from NACR]. Currently, most cardiac patients (77%) receive centre (hospital)-based, group CR[8]. Travelling to centres and dislike of group exercise are key barriers to participation in centre-based programmes[6,10,11]. That women, people from black and minority ethnic groups, and those living in high deprivation are less likely to attend centre-based CR[8], indicates that centre-based approaches are exclusionary. Home-based CR thus offers a cost-effective approach to improving CR uptake by people with HF, resulting in better health and wellbeing outcomes. The 2020 COVID-19 pandemic, and the policy by many countries of home lockdown to maintain social distancing, has dramatically underlined the urgent need for alternatives to centre-based models of healthcare provision.

We co-developed (with clinicians/practitioners, people with health failure, their caregivers and service commissioners) an evidence- and theory-based, novel home CR intervention for people with HF: Rehabilitation EnAblement in CHronic Heart Failure (REACH-HF)[12]. A multi-centre randomised trial demonstrated that the addition of REACH-HF to usual medical care resulted in a clinically important improvement in HRQoL of people with HF, when compared to usual care alone[13]. Economic modelling showed that the REACH-HF intervention to be both low-cost (at £417/patient) and cost effective[14]. However, there remains a paucity of data regarding the extent to which

SCOT:REACH-HF Protocol paper v.3.1 040820

1
2
3 introducing home-based CR for HF increases CR uptake[6,15]. Moreover, it is uncertain that the
4 positive outcomes identified in the REACH-HF RCT can be replicated in a 'real world' setting, and
5 what key considerations are with regards to embedding such an intervention in everyday practice.
6
7

8
9 At present, relatively few evidence-based healthcare interventions become embedded in routine
10 clinical practice[16]. Factors contributing to this include: weak external validity of efficacy trials;
11 intervention developers' lack of consideration for scale-up; trial design issues; and development of
12 interventions that are overly-theoretical[17-19]. Where implemented, evaluations often consider
13 individual-level health professional performance, targeting knowledge, routines and
14 attitudes[20,21]. Individuals play a significant role in implementation, in that they dynamically
15 engage with interventions while, to varying degrees, embodying their own interests and motivations
16 and those of their profession, organisation and culture[22,23]. It is crucial also to understand
17 community, organisational, system and policy-level influences on the embedding of innovative
18 practice[22].
19
20
21
22
23
24
25

26 Running parallel to a similar implementation study already underway in England and Northern
27 Ireland[24], our study seeks to understand the organisational and other wide-ranging influences
28 affecting the implementation of REACH-HF in Scotland, in order to inform potential large-scale roll-
29 out of the intervention. A key factor shaping implementation is that a given intervention may not
30 produce the same effects when transferred from one context to another and, crucially, from a
31 randomised trial to the 'real world'. Target population characteristics may differ in key ways, such as
32 geographical location (urban/rural) or relative deprivation. Moreover, there may be significant
33 contextual differences between sites and teams delivering a healthcare intervention, such as the size
34 of the team or familiarity with a given approach. Such contextual differences may produce
35 adaptations in what is delivered and how (i.e. impacting fidelity to the intervention design). This may
36 in turn shape intervention results – including any proven benefit – when compared with an RCT[25].
37 Adaptability to context may also impact the sustainability of an intervention, that is, the extent to
38 which it is embedded in everyday practice[22].
39
40
41
42
43
44
45
46
47

48 We draw specifically from UK Medical Research Council (MRC) guidance on evaluation of complex
49 interventions, particularly using process evaluation methodology[26]. Process evaluation is an
50 established means by which to understand implementation by assessing: fidelity (the degree to
51 which the intervention was delivered as intended); context (barriers to and facilitators of
52 implementation, including those that might explain variation in outcomes), and mechanisms of
53 impact[23]. As the mechanisms by which the REACH-HF intervention changes behaviour have been
54 described and explored elsewhere[12,13], we focus here on fidelity and context in the new delivery
55 setting. Integration of process and outcome data can generate better understanding of, for example,
56
57
58
59
60

SCOT:REACH-HF Protocol paper v.3.1 040820

whether and how adaptations to implementation, or differences amongst sites, explains any observed variation in outcomes, as well as informing improvements for future roll-out.

METHODS AND ANALYSIS

Study design

A mixed-method implementation study comprising a multi-centre prospective cohort study and nested process and economic evaluations.

The overarching aim of this study is to assess the real-world implementation REACH-HF for people living with heart failure and their caregivers in Scotland. Our research questions are:

1. What are the service level facilitators and barriers to the implementation of REACH-HF?
2. How do 'real-world' patient and caregiver outcomes compare with those seen in a prior clinical trial?
3. What is the estimated economic (health and social) impact of implementing REACH-HF in Scotland?

Informed by process evaluation methodology, the study protocol detailed below is thus organised around four key components, which contribute to answering these questions:

- **fidelity** of implementation: what was implemented and how closely this reflected what was intended (i.e. the original REACH-HF intervention) [RQ1&2];
- **contextual factors**: barriers to, and facilitators of, implementation, as perceived by the health professionals and service organisers involved; 'background noise' to implementation [RQ1];
- **CR participant-related outcomes**: whether, and to what extent, improvements in patient outcomes seen in the REACH-HF RCT are replicated [RQ2];
- **economic impact**: health and social implementation costs [RQ3].

The study will be conducted across Scottish NHS Health Board CR services which, as early adopters of REACH-HF, will be designated as 'Beacon Sites'. (The use of early adopters to model intervention implementation is itself one means of contributing to routinisation/embedding of innovative practice[22].) A national application process followed promotion at national conferences, and contact letters to HF specialist nurses and cardiac rehabilitation leads. This resulted in recruitment of four sites across six NHS Health Boards to act as Beacon Sites: NHS Ayrshire and Arran; NHS Lanarkshire; NHS Forth Valley; and NHS Highland, Orkney, and Shetland (combined to act as one site

SCOT:REACH-HF Protocol paper v.3.1 040820

1
2
3 due to small patient numbers). Sites were selected for their ability to commit to delivery of REACH-
4 HF, and for geographic spread.
5

6
7 We will assess patient outcomes before and after administering the 12-week programme with 35
8 people with heart failure (140 total). Members of the HF team at each site will be interviewed.
9

10 Detailed information of the costs and utilisation of the provision of the REACH-HF programme will be
11 collected. Given the ongoing COVID-19 crisis, the start of data collection for the study has been
12 delayed, but will begin in November 2020. NHS Greater Glasgow and Clyde will act as study sponsor.
13
14
15

16 17 18 **Sample and recruitment** 19

20 The study will be conducted across Scottish NHS 'Beacon Sites'. People with heart failure (HF) are
21 eligible if they: are aged 18 years or over; have a confirmed diagnosis of systolic (reduced ejection
22 fraction) heart failure within the past five years; have experienced no deterioration of HF symptoms
23 in the preceding two weeks resulting in hospitalisation or alteration of HF medication; and are
24 deemed suitable for CR by their local clinical team. We will exclude anyone who: has undertaken CR
25 in the preceding 12 months; has medical contraindications to exercise testing or training; is in a long-
26 term care establishment, or unwilling/unable to travel to research assessments or accommodate
27 home visits; is unable to understand the study information or unable to complete the outcome
28 questionnaires. Patients with a caregiver will also be invited to participate. Patients with no
29 caregiver, or whose caregivers do not wish to participate, are still eligible take part in the study.
30
31
32
33
34
35
36

37 Sites will recruit people with HF, using their usual means of CR referral to introduce the study. This is
38 likely to include a variety of pathways such as: people with HF referred for CR from acute or primary
39 care; review of patients held on site HF databases; and approaching people with HF at outpatient
40 appointments/home-visits. Potential participants will be provided with invitation letters, information
41 sheets, and reply slips for both them and their caregiver (if applicable), and those interested in
42 participation will be asked to instigate contact with the research team by returning the reply slips.
43
44
45
46
47

48 Fig 1 outlines the participation pathway for people with HF.
49

50 [FIGURE 1 HERE]
51

52 A maximum of 20 individual interviews will be conducted with health professionals involved in the
53 delivery of SCOT:REACH-HF, near the end of the intervention period. These will include the trained
54 facilitators (typically CR nurses or physiotherapists), as well as other key individuals involved in co-
55 ordinating and commissioning CR (such as senior clinicians and service management). There may be
56 some variation in participant roles due to the differing structures of local HF teams. We will use a
57
58
59
60

SCOT:REACH-HF Protocol paper v.3.1 040820

1
2
3 combination of convenience and purposive sampling, offering the opportunity to participate to all
4 those delivering REACH-HF, and those identified as having a key role in service planning, to ensure
5 capture of diverse perspectives. A participant information sheet will be provided to all potential
6 interviewees, and they will have adequate time to consider participation and ask questions about
7 the interview process. Written consent will be obtained prior to face-to-face interviews. Where
8 interviews are to be conducted by telephone, consent forms will be completed digitally and returned
9 by email, and verbal consent recorded digitally.
10
11
12
13
14
15
16
17

18 **The intervention**

19
20 REACH-HF is a home-based, health professional-facilitated, 12-week CR programme supporting self-
21 care in patients with HF. Three health professionals with CR and/or HF experience from each Beacon
22 Site will attend a two-day online REACH-HF training course facilitated by the Heart Manual
23 Department, NHS Lothian (formerly a three day face-to-face training delivered in Edinburgh, the
24 course has been adapted to accommodate current restrictions). Training focuses on the seven steps
25 of successful facilitation of REACH-HF (in turn based on a person-centred care approach): 1) Build
26 rapport; 2) Assess needs and build understanding of HF; 3) Support self-management and progress
27 monitoring; 4) Discuss exercise and wellbeing; 5) Summarise and plan next steps; 6) Review
28 progress; 7) Support long-term maintenance. As such, training includes sessions on psychology,
29 behaviour change, physical activity, engaging caregivers, and newly adapted components to address
30 intervention delivery during the Covid-19 pandemic. Following training, facilitators are then asked
31 to implement REACH-HF. The programme – described in detail elsewhere[11,12] – is outlined in BOX
32
33
34
35
36
37
38
39
40
41 A.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BOX A: The REACH-HF Intervention

- *The Heart Failure Manual*, which provides information about HF for the person with heart failure, to increase understanding of the condition and address common misconceptions.
- Information on and strategies for managing HF, and further relevant advice on, for example, managing lifestyle risk, managing depression and anxiety, and getting support from others.
- A choice of two exercise training programmes: a chair-based programme (via DVD and online) and a walking programme; with a recommendation that these should be engaged in three times weekly, alongside general physical activity.
- A stress-management programme, with relaxation techniques (provided in the manual and in audio format) to help cope with anxiety and depression.
- A progress tracker designed to facilitate an individual's learning from experience through self-monitoring of behaviour and symptoms. (This prompts help-seeking as appropriate).
- *A Family and Friends Resource* to increase caregiver understanding of HF, to enable them to support the person with HF's self-care and wellbeing.
- Face-to-face and telephone facilitation over 12 weeks by a health professional trained to deliver the REACH-HF programme.

Measures / data collection

Patient and caregiver outcome data will be collected during an initial assessment appointment by a designated member of the Beacon Site team trained in data collection by the REACH-HF team, and via self-completion questionnaires (either postal or online, as per participants' preference). Data will be collected at baseline - before commencing with the REACH-HF programme - and four months following baseline, which coincides with the end of intervention delivery period (see Figure 1).

Fidelity assessment: Facilitator-patient interactions (face-to-face and/or phone) for 65 participants will be audio-recorded. Recordings will be assessed using our established fidelity assessment checklist (described in detail elsewhere [12]). This 12-item checklist focuses on assessing inclusion by facilitators of key processes such as patient-centred communication, making a plan of action, and encouraging self-monitoring of progress. Facilitators will also be asked to complete a brief self-rated

SCOT:REACH-HF Protocol paper v.3.1 040820

1
2
3 fidelity checklist after every session. This comprises questions on the same 12 programme
4 components and asks facilitators to rate occurrences of each feature (absent, minimal, some,
5 sufficient, good, very good, excellent). An independent observer-rating is resource-intensive, while
6 self-rated assessment may provide a pragmatic, real-world alternative to monitor delivery quality.
7
8 We will also explore (in the interviews below) whether use of the checklist facilitates/encourages
9 reflexive practice and, in doing so, quality of implementation.
10
11
12
13
14
15

16 Context: We seek to capture data on barriers to and facilitators of implementation REACH-HF by
17 interviewing health professionals at each Beacon Site. We anticipate conducting up to 20 individual
18 interviews, which will be audio-recorded and transcribed verbatim for analysis. Interviews will be
19 conducted by CP face-to-face or by phone, as per the participant's preference. Normalisation
20 Process Theory [27] will be used as a theoretical framework to guide data collection, analysis and
21 interpretation. A flexible topic guide - informed by the four constituent constructs of NPT
22 (coherence, cognitive participation, collective action, reflexive monitoring), the existing literature on
23 cardiac rehabilitation, and the key aims of the implementation study - will facilitate generation of
24 rich data, as well as enabling capture of factors unanticipated by the research team (see Appendix
25 1).
26
27
28
29
30
31
32

33 Additional ad hoc contextual data from each site will be collated centrally (by CP) in one
34 implementation log (Excel file) which will also capture overall 'background noise' to implementation
35 (such as the impact of the COVID-19 pandemic) which will contribute to the contextual analysis.
36
37
38
39
40

41 CR participant-related outcomes: Data will be recorded in a Case Report Form (CRF), and participants
42 will be offered the option of a paper self-completion questionnaire or a secure individual link sent by
43 email to complete the questionnaire online. At the baseline appointment, after obtaining written
44 consent, Beacon Site teams will collect medical history from the participants' hospital and primary
45 care records, including: comorbidities (number and severity scored with Charlson co-morbidity index
46); New York Heart Association (NYHA) class; heart failure aetiology; concomitant heart failure
47 medication and presence of implantable heart failure devices.
48
49
50
51
52

53 Participants will provide detailed sociodemographic data (age, gender, ethnicity, weight,
54 employment status, education level, smoking status) at baseline. The following participant outcomes
55 will be assessed: disease-specific health-related quality of life (HRQoL) measured using the
56 Minnesota Living with Heart Failure Questionnaire; generic quality of life (five-dimension EuroQol
57 (EQ-5D-5L) scale); psychological wellbeing (Hospital Anxiety and Depression Scale (HADS)); patient-
58
59
60

SCOT:REACH-HF Protocol paper v.3.1 040820

1
2
3 reported outcome measure for cardiac rehab (PROM-CR); hospitalisations and primary care contacts
4 (number, reason, duration); adverse events (e.g. skeletomuscular injury); health literacy (Health
5 Literacy Questionnaire (HLQ)); and, if possible, exercise capacity via an incremental shuttle walk test
6 (if face-to-face assessment possible). Caregiver outcomes are: generic quality of life (EQ-5D-5L);
7
8 psychological wellbeing (HADS); Family Caregiver Quality of Life Scale questionnaire (FamQoL);
9
10 Caregiver Burden Questionnaire HF (CBQ-HF); Caregiver Contribution to Self-care of HF Index
11
12 questionnaire (CC-SCHFI). The same outcomes will be collected at the four-month follow up.
13
14
15
16
17

Economic impact: Data will be collected to allow the costing of the REACH-HF intervention delivery.
18
19 These will include time input from REACH-HF facilitators, supervision for facilitators, training costs
20 for facilitators and consumables. Unit costs for resource use will be sought from national published
21 or NHS sources. Data from each site will be recorded in the implementation log (excel file, as above).
22
23
24 Additionally, facilitators will be asked to complete a Facilitator Log for each participant. This log is a
25 one-page pro forma designed to capture time, expenditure and any other resources required for the
26 implementation of REACH-HF, as well as any adaptations made to the intervention for individual
27 patients. As such it will capture essential data for the fidelity and economic analyses. Completed
28 forms will be returned to the research team for data entry and analysis.
29
30
31
32
33
34
35

36 **Data management**

37
38 Data management will follow the principles of Good Clinical Practice and supported by the
39 University of Glasgow Clinical Trials Unit (GCTU). An electronic CRF (eCRF) developed by the GCTU
40 will capture all data noted above. Access to the eCRF will be restricted, via a study-specific web
41 portal, with only authorised personnel able to make entries. RT or their designee will be responsible
42 for all eCRF entries, and will confirm that data are accurate, complete and verifiable. Entries from
43 participant medical records will be made locally by Beacon Site staff trained by the research team.
44
45 Where data are entered by the participant into a paper CRF, completed anonymous questionnaires
46 will be returned by post to the University of Glasgow for data entry. Where completed by the
47 participant electronically, data will be entered directly into a participant-facing version of the eCRF.
48
49 Where practical, data will be validated at the point of entry into the eCRF. Any additional data
50 discrepancies will be flagged to RT and any changes recorded to maintain a complete audit trail
51 (reason, date and who made the change). Data will be stored in a MS SQL Server database. Direct
52 access to the study web portal will be granted, on request, to authorised representatives of the
53
54
55
56
57
58
59
60

SCOT:REACH-HF Protocol paper v.3.1 040820

Sponsor, host institution and regulatory authorities to permit trial-related monitoring, audits and inspections.

The qualitative, fidelity and economic impact components of the study will be conducted by UoG under the direction of RT. Transcription will be undertaken by a specialist service with whom UoG has an ongoing contractual arrangement and confidentiality agreement. All data (Excel files, audio recordings and anonymised transcripts, stored separately) will be kept for at least ten years in line with UoG Research Governance Framework Regulations for clinical research. Data will be stored confidentially on password-protected servers maintained on the UoG network. Anonymised data will be made available to other legitimate researchers on request, as per study consents.

The study will be overseen by the Project Management Group (co-applicants) and Project Advisory Group (national CR experts) – see Appendix 2 for membership.

Data Analysis

We require 130 participants to detect pre-post intervention change in the Minnesota Living with Heart Failure Questionnaire (MLFHQ) scores to achieve the minimal important difference [13] ≥ 5 points. This calculation is based on a MLFHQ standard deviation of 24 points, within patient pre-post correlation ($r=0.72$) and attrition rate of $\leq 10\%$ as seen in our multi-centre RCTs (refs). There is no formal sample size calculation for the number of caregivers participating in this study.

Fidelity: Fidelity data will be analysed by CP. Fidelity checklist scores will be collated at facilitator, site, and total sample levels. We will present descriptive statistics (means, ranges), using the same analytic approach as the original REACH-HF trial [13]. In brief, the fidelity checklist uses an established 0-6 scale (Dreyfus scale of clinical skills acquisition[28]) to rate clinical skills, and is anchored such that a score of three or more represents adequate delivery quality for each item. Fidelity outcomes will be compared with the REACH-HF RCT [13], and analysed alongside self-rated fidelity scores. Overall findings will be integrated with the context and CR participant-related outcome data findings.

CR participant-related outcomes: The primary analyses for primary and secondary quantitative outcomes will be based on a within-patient comparison in participants with complete outcome data at four months. We will examine the characteristics of any patients who withdraw, and conduct secondary analysis based on imputation of their missing outcome data. All within-patient outcome comparisons will be presented as mean difference with 95% CI. The outcome effect size seen in the Beacon Sites will be indirectly compared to the changes found in the REACH-HF trial [13]. Statistical

1 SCOT:REACH-HF Protocol paper v.3.1 040820

2
3 analysis will be conducted by RT using STATA v.15. Descriptive statistics will be presented in order to
4 describe study population characteristics.
5

6
7 Context: Verbatim transcripts (Word documents) will be pseudonymised (removing any potential
8 indicators of personal identity or site) and uploaded into NVivo 12 qualitative software to facilitate
9 data management. A coding framework will be developed, informed by the constructs of NPT noted
10 above, and taking an approach informed by the Framework method[29]. This approach will also for
11 consideration of unanticipated issues.
12
13
14

15
16 Following this categorising stage, a further interpretive stage will see data examined across sources
17 (professional role) and cases (sites). This will facilitate understanding of contextual factors shaping
18 implementation of REACH-HF in context, and development of potential explanations for
19 commonalities and differences between our findings and the previous RCT.
20
21
22

23
24 A subsequent integrative analysis will be conducted to bring together each analytic component
25 (fidelity, context, CR participant-related outcomes). Integrative analysis will involve placing all
26 relevant data in one integrative matrix and assessing for synergies which indicate our key findings,
27 again guided by the NPT framework. Placing key findings in a matrix alongside those from the
28 original REACH-HF RCT will also facilitate understanding of the 'real world' effectiveness of the
29 intervention. First stage coding, interpretation will be conducted by CP in consultation with RT.
30 Integrative analysis will be conducted by CP and RT with input from the project management group.
31
32
33
34
35

36 Economic impact: Economic analysis will focus on assessing the cost of the delivery of REACH-HF in
37 the four Beacon Sites, that is, the additional (incremental) costs associated with delivery of the HF
38 Manual, when added to usual care. Healthcare costs will be estimated using resource use data
39 collected within the study, and unit costs for resource use from national published/NHS sources.
40 Resource use is expected to consist of time input from REACH HF facilitators, supervision for
41 facilitators, training costs for facilitators and consumables (e.g. intervention booklets for participants
42 and facilitators). Data on facilitator time will be captured by facilitators at participant level, using the
43 Facilitator Log described above. Economic analysis will be conducted by CP and RT alongside the
44 main statistical analysis.
45
46
47
48
49
50
51
52
53

54 **Patient Public Involvement (PPI)**

55
56 People with heart failure and their caregivers had an extensive input into the development of the
57 REACH-HF intervention, and a substantial body of data on patient experiences has been generated
58 through interviews with RCT participants [13,14]. We have established a standing PPI group for
59
60

SCOT:REACH-HF Protocol paper v.3.1 040820

SCOT:REACH-HF led by TI, involving people with heart failure and their caregivers, who are independent of the study. Four meetings of the PPI group will be convened during the study to review participant-facing materials, advise on dissemination, and provide input on any participant related problems that may arise, such as recruitment and retention.

Discussion

Approaches to implementation science are varied[23]. We draw on MRC guidance on the evaluation of complex interventions which highlights that, while RCTs are viewed by many as the gold standard for demonstrating efficacy, they do not tell policy makers or service commissioners whether an intervention would produce the same outcomes in their context[26]. A process evaluation approach produces understanding of implementation by assessing fidelity, context, and mechanisms of impact[25]. As the mechanisms of REACH-HF are explored elsewhere[12,13], this study focuses on fidelity and context in the new delivery setting.

Most complex interventions would be expected to see some adaptation as they are transferred into real world settings[23] (variable by how much contextual factors have been considered in the design process). Indeed, some adaptability is in fact desirable in order to support effectiveness[30]. In order to assess if and how any adaptations might have impacted the overall integrity of the intervention, it is vital to a) have a clear picture ahead of implementation of what the active components of an intervention are, and b) understand how closely delivery follows what is intended[30]. Hence, we include above a description of the intervention's constituent parts, and include in the study design a multi-pronged approach to assessing fidelity.

There are limitations on the degree to which novel interventions become embedded in routine clinical practice. However, these limitations can be ameliorated by well-considered studies of implementation. By operationalising a tailored process evaluation methodology, we aim to assess such implementation, and the translation from RCT to 'real world', by paying particular attention to: fidelity to the intended programme, contextual factors shaping delivery, and how these may explain any differences measured in participant outcomes.

Our findings will inform potential larger-scale roll-out of REACH-HF, offer guidance to policy makers and CR commissioners, inform contextual adaptations, and facilitate diffusion and embedding of home-based CR for people with heart failure in the UK.

Strengths and limitations

1 SCOT:REACH-HF Protocol paper v.3.1 040820

2
3 This study will formally assess of the implementation of a novel home-based cardiac rehabilitation
4 programme for heart failure in the context of NHS Scotland. It employs mixed methods which
5 integrates quantitative and qualitative approaches to understanding the implementation process.
6
7 Moreover, our study will facilitate a communication channel between researchers and
8 implementers, in order to support high quality services for people with heart failure, and establish
9 four key Beacon Sites that have the potential to model intervention roll-out, should that be adopted
10 more widely. Although limited to four sites geographical sites, these sites incorporate a wide range
11 of settings including urban and rural populations. An additional strength is the adaptation of the
12 study to the restrictions of the ongoing Covid-19 pandemic, and the potential to assess
13 implementation of support for self-care for a potentially vulnerable population.
14
15
16
17
18
19
20
21
22

23 **ETHICS AND DISSEMINATION**

24
25 The study has been given ethical approval by the West of Scotland Research Ethics Service
26 (reference 20/WS/0038, approved 25/03/2020). Written informed consent will be obtained from all
27 participants. The study is listed on the ISRCTN registry with study ID ISRCTN53784122. The research
28 team will ensure that the study is conducted in accordance with both General Data Protection
29 Regulations and the University of Glasgow's Research Governance Framework. Findings will be
30 reported to the funder and shared with Beacon Sites, to facilitate service evaluation, planning and
31 good practice. To broaden interest in, and understanding of REACH-HF, we will seek to publish in
32 peer-reviewed scientific journals and present at stakeholder events, national and international
33 conferences.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SCOT:REACH-HF Protocol paper v.3.1 040820

REFERENCES

1. National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management. *NICE Guideline NG106*. London: NICE; 2018.
2. Conrad N, Judge A, Tran J et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. *Lancet* 2018;391(10120):572-80.
3. Mamas MA, Sperrin M, Watson MC et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. *Eur J Heart Fail* 2017;19(9):1095-104.
4. Braunwald, E. The war against heart failure: The Lancet lecture. *Lancet* 2015;385(9970):812-24.
5. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. *Int J Cardiol* 2014;171(3):368-76.
6. Dalal HM, Doherty P, Taylor RS. Cardiac rehabilitation. *BMJ* 2015;351:h5000.
7. Long L, Mordi IR, Bridges C et al. Exercise-based cardiac rehabilitation for adults with heart failure. *Cochrane Database Syst Rev* 2019;1:Cd003331
8. Taylor RS, Walker S, Smart NA et al. Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure: individual participant meta-analysis. *J Am Coll Cardiol* 2019;73(12):1430-43.
9. Spaling MA, Currie K, Strachan PH, Harkness K, Clark AM. Improving support for heart failure patients: A systematic review to understand patients' perspectives on self-care. *J Adv Nurs* 2015;71(11):2478-89.
10. National Cardiac Audit Programme. National Heart Failure Audit: 2016/17 summary report. London: NICOR; 2017.
11. The National Audit of Cardiac Rehabilitation: annual statistical report 2018. London: British Heart Foundation;2018.
12. Greaves CJ, Wingham J, Deighan C et al. Optimising self-care support for people with heart failure and their caregivers: Development of the Rehabilitation Enablement in Chronic Heart Failure (REACH-HF) intervention using intervention mapping. *Pilot Feasibility Stud* 2016;2:37.

SCOT:REACH-HF Protocol paper v.3.1 040820

13. Dalal HM, Taylor RS, Jolly K et al. The effects and costs of home-based rehabilitation for heart failure with reduced ejection fraction: The REACH-HF multicentre randomized controlled trial. *Eur J Prevent Cardiol* 2019;26(3):267-72.
14. Taylor RS, Sadler S, Dalal HM et al. The cost effectiveness of REACH-HF and home-based cardiac rehabilitation compared with the usual medical care for heart failure with reduced ejection fraction: a decision model-based analysis. *Eur J Prev Cardiol* 2019;26(12):1252-1261.
15. Santiago de Araujo Pio C, Chaves GS, Davies P, Taylor RS, Grace SL. Interventions to promote patient utilisation of cardiac rehabilitation. *Cochrane Database Syst Rev* 2019;2:Cd007131.
16. Balas EA, Boren SA Managing Clinical Knowledge for Health Care Improvement, in *Yearbook of Medical Informatics 2000: Patient-centered Systems*. 2000; Stuttgart: Schattauer: 67-70.
17. Schliep ME, Alonzo CN, Morris MA. Beyond RCTs: Innovations in research design and methods to advance implementation science. *Evid Based Commun Assess Interv* 2018;11(3-4):82-98.
18. Goldstein H, Olswang L Is there a science to facilitate implementation of evidence-based practices and programs? *Evid Based Commun Assess Interv* 2017;11(3-4):55-60.
19. Glanz K, Bishop DB. The role of behavioral science theory in development and implementation of public health interventions. *Annu Rev Public Health* 2010;31:399-418.
20. Grol RPTM, Bosch MC, Hulscher MEJL, Eccles MP, Wensing M. Planning and Studying Improvement in Patient Care: The Use of Theoretical Perspectives. *Milbank Q* 2007;85(1):93-138.
21. Grimshaw JM, Thomas RE, MacLennan G et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. *Health Technology Assessment*. 2004;8(6):1-72.
22. Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O. Diffusion of Innovations in Service Organizations: Systematic Review and Recommendations. *Milbank Q*. 2004;82(4):581-629.
23. Damschroder LJ, Aron DC, Keith RE et al. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. *Implementation Sci* 2009;4(50).
24. Daw P, van Beurden S, Greaves C et al. Getting evidence into clinical practice: Protocol for evaluation of the implementation of a home-based cardiac rehabilitation programme for patients with heart failure. *BMJ Open*. Accepted (May 2020).
25. Fixsen DL, Naoom SF, Blase KA, et al. *Implementation Research: A Synthesis of the Literature*. Tampa: University of South Florida; 2005.

SCOT:REACH-HF Protocol paper v.3.1 040820

26. Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions: Medical Research Council guidance. *BMJ* 2015;350:1258.

27. May CR, Cummings A, Girling M et al. Using Normalization Process Theory in feasibility studies and process evaluations of complex healthcare interventions: a systematic review. *Implementation Sci* 2018;13(1):80.

28. Dreyfus HL. The Dreyfus model of skill acquisition. In J. Burke (ed.) *Competency based education and training*. 1989; London: Falmer Press.

29. Ritchie J, Spencer L. Qualitative data analysis for applied policy research, in Bryman A, Burgess RG (eds.) *Analysing qualitative data*. 1994; London: Routledge.

30. Hawe P, Shiell A, Riley T. Complex interventions: how “out of control” can a randomised controlled trial be?. *BMJ* 2004;328(7455):1561-3.

AUTHOR CONTRIBUTIONS

The study was conceived of and designed by RT, HD and the REACH-HF collaboration. CP and RT drafted the manuscript. RT and CP will lead recruitment and set-up of Beacon Sites, and CP will oversee day-to-day project management. RT, CK and CP secured all relevant ethical approvals for the project and prepared all study documentation, to which PD also contributed. AC designed the PROM-CR measure. CP and RT will conduct study analysis and write-up. TI will lead on coordinating PPI. JC and CM will provide project supervision and oversight. All authors reviewed and approved the final version of this protocol for publication.

FUNDING STATEMENT


This work is supported by Heart Research UK (grant SC09/19) and conducted by the MRC/CSO Social and Public Health Sciences Unit, University of Glasgow (grants SPHSU14 and MC_UU_12017/14). RT is part-funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research scheme (project reference RP-PG-1210-12004).

COMPETING INTERESTS STATEMENT

None.

FIGURE LEGEND

Figure 1 - SCOT:REACH-HF Participant Pathway



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

APPENDIX 1 - SCOT:REACH-HF Interview Topic Guide

Introduction:

- Explain interview purpose / study aims
- Emphasise no right/wrong answers, can decline to answer at any time
- Opportunity for questions
- Check consent, permission to record

General:

- Tell me a little about yourself (e.g. Job title, key roles/responsibilities)

Starting out with REACH-HF

- What was your first impression of REACH-HF?
- Tell me about your experience of the facilitator training (if applicable)
- Was the training sufficient to enable you to deliver REACH-HF? (*PROMPT anything you would have liked to see done differently, added/left out, additional resources?*)
- Was there anything that made it easier/more difficult for you to take part in the training?
- To what extent do you feel you started with a clear understanding of what you were being asked to do?

Implementing REACH-HF (facilitators)

- Tell me about when you first began delivering the intervention (*PROMPT first patient session e.g. initial experiences, concerns, information gaps, confidence*)
- How has delivering REACH-HF differed from your usual way of working?
- Was there anything that made it easier/more difficult for you to deliver the intervention? (*PROMPT adequate support*)
- What did you see as being the main purpose of REACH-HF? (*PROMPT has that changed?*)
- What, if any, changes did you make to how you delivered the intervention as time went on (e.g. to suit your way of working, or the patient's needs)? (*PROMPT for details*)
- How did you find the task of completing the post-session checklist (after recorded sessions)? (*PROMPT e.g. useful, additional burden etc*)

Implementation of REACH-HF (non-facilitators)

- Tell me about your impressions of how the delivery of REACH-HF went in your area
- Was there anything that made it easier/more difficult for REACH-HF to be delivered in your area?
- Can you tell me about any additional resources that were needed for REACH-HF? Or changes in roles/responsibilities?

Embedding REACH-HF

- How, if at all, has delivering REACH-HF changed the way you work? (*PROMPT changes specific to home self-care; changes to way team works; if expect likely to be lasting change*)

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- How easy has it been to integrate REACH-HF into your usual work? (*PROMPT good fit or not*)
- What changes, if any, would you make to REACH-HF to suit your way of working?
- Of those you work with, who is it that's driven REACH-HF forward? (*PROMPT role, what they've done to support delivery; can include self*)
- In what way, if any, has implementing REACH-HF changed working relationships in your team?
- Is there anything else that would make it easier for REACH-HF to become part of routine practice for your team? (*PROMPT additional skills, training, support*)
- Are your team evaluating the impact of REACH-HF on your service? (*PROMPT details*)
- What do you think is likely to be the future of REACH-HF in your service? (*PROMPT likely to become routine practice?*)

Overall impressions of REACH-HF

- To what extent do you feel that offering the intervention has been worthwhile?
- When you've discussed as a team how REACH is going, can you tell me about how those conversations have gone? (*PROMPT similarities/differences around e.g. aims, expected benefits as a mode of delivery*)
- What, if anything, do you see as being the value of the intervention:
 - For you
 - To your patients (if applicable)
- Has the COVID-19 pandemic impacted your delivery of REACH-HF/CR?
- What are your overall views on REACH-HF? (*PROMPT anything not already noted*)
- Is there anything else you think it is important for the research team to know?

Close

- Any questions?
- Feedback on interview?
- Thank participant and close.

APPENDIX 2 – PROJECT MANAGEMENT GROUP AND INDEPENDENT ADVISORY GROUP MEMBERSHIP

Project Management Group *(To oversee the progress and delivery of the project)*

Prof Rod Taylor - Chief Investigator, University of Glasgow

Dr Carrie Purcell – Project Manager, University of Glasgow

Dr Hayes Dalal – REACH-HF co-Chief Investigator / Honorary Clinical Associate Professor, University of Exeter / Senior Clinical Researcher, Royal Cornwall Hospitals NHS Trust

Dr Clare Murphy - Co-Applicant, NHS Greater Glasgow & Clyde / Scottish National Advisory Committee for Heart Disease – Heart Failure Subgroup Chair and Clinical Lead

Dr Aynsley Cowie – Co-Applicant, Consultant Physiotherapist in Cardiology, NHS Ayrshire & Arran / BACPR Council Member

Dr Tracy Ibbotson – Co-Applicant, Patient and Public Involvement and Engagement Lead, College of Medical, Veterinary and Life Sciences, University of Glasgow

Mrs Claire Kerr – Project Manager, Robertson Centre for Biostatistics, University of Glasgow

Project Advisory Group *(To provide independent advice and direction to the project)*

Ms Frances Divers – Cardiac Rehabilitation Champion, NHS Scotland (chair)

Dr Edwin Jesudason – Cardiac Rehabilitation Clinical Lead, NHS Scotland

Mr Richard Forsyth – Health Services Engagement Lead, British Heart Foundation Scotland

Mr Nick Hartshorne-Evans – CEO, Pumping Marvellous (patient group)

Ms Louise Taylor – Head of Services, Heart Manual Department, NHS Lothian

Dr Hayes Dalal – REACH-HF co-Chief Investigator / Honorary Clinical Associate Professor, University of Exeter / Senior Clinical Researcher, Royal Cornwall Hospitals NHS Trust

Ms Helen Wilson, Head of Research, Heart Research UK (observer)